Immunovaccine to Present at Biotech Showcase 2012
HALIFAX, NOVA SCOTIA -- (MARKET WIRE) -- 01/05/12 -- Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine developer, will present at Biotech Showcase in conjunction with attending the J.P. Morgan Healthcare Conference from January 9-12, 2012 in San Francisco, CA.
John J. Trizzino, Immunovaccine's chief executive officer, will be a panelist at the Biotech Showcase infectious disease session on Monday, January 10, 2012 at 8:00 a.m. pacific time. Mr. Trizzino will also make a formal company presentation at Biotech Showcase on Wednesday, January 11, 2012 at
3:30 p.m. pacific time in the Track C - Mission II room.
During his company presentation, Mr. Trizzino will highlight the recently announced start of Immunovaccine's Phase I clinical trial for DPX-Survivac, a survivin-based therapeutic cancer vaccine. He will also discuss the Phase I results for DPX-0907 (a therapeutic cancer vaccine targeting patients with breast, ovarian or prostate cancer) and the various research collaborations applying the DepoVax™ vaccine adjuvanting platform to vaccine candidates in development.
The Biotech Showcase provides companies an opportunity to present to investors and biopharmaceutical executives during the course of the annual JP Morgan Healthcare conference, the industry's largest annual healthcare investor conference. www.biotechshowcase.com
About Immunovaccine
Immunovaccine Inc. develops vaccines formulated in its vaccine delivery platform for cancer therapy and infectious disease. The Company's DepoVax™ platform is a patented lipid delivery system that presents antigens plus adjuvant to the immune system for a prolonged period and has the potential to enhance immune responses. Immunovaccine has taken its platform technology and proprietary cancer vaccine into Phase I human trials and has demonstrated its safety and immunogenicity potential. The Company is also capitalizing on the broad potential of its delivery platform by creating new DepoVax-based vaccines through multiple development collaborations. In addition to the Company's human health vaccine strategy, it continues to capture value from animal health vaccine applications. Pfizer Animal Health has licensed the Company's delivery technology platform to develop vaccines for livestock. www.imvaccine.com or www.twitter.com/immunovaccine.
This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts: Immunovaccine Inc. Jennifer Ayotte Director Communications (902) 209-4704 [email protected] www.imvaccine.com Tiberend Strategic Advisors, Inc. Andrew Mielach (212) 827-0020 [email protected]
Source: Immunovaccine Inc.
Released January 5, 2012